<DOC>
	<DOCNO>NCT00894062</DOCNO>
	<brief_summary>Stent thrombosis important issue drug elute stent . Incomplete endothelial coverage neointimal coverage strut drug elute stent ( DES ) implantation could possible cause stent thrombosis . Therefore , theoretically dual antiplatelet therapy continue prevent stent thrombosis complete reendothelialization . But , detection endothelial coverage stent possible available intravascular device clinical practice . Among currently available intravascular device , intravascular optical coherence tomography ( OCT ) could give clear identification thin layer neointima high-resolution ( 10-20 μm ) compare intravascular ultrasound ( 100-150 μm ) . Previous OCT study show significant different pattern neointimal coverage bare metal stent ( BMS ) DES . In investigator ' experience , also differences neointimal coverage among DESs , especially zotarolimus elute stent ( ZES ) . ZES know associate significantly neointimal coverage SES 8 month intravascular ultrasound ( IVUS ) . Both everolimus eluting stent ( EES ) ZES resolute recently introduce . The efficacy suppress neointimal growth ZES resolute EES might improve , safety neointimal coverage need evaluate human coronary artery . Therefore , study investigate pattern neointimal coverage stent ZES resolute EES 9 month stent implantation .</brief_summary>
	<brief_title>Comparison Neointimal Coverage Between Zotarolimus Eluting Stent Everolimus Eluting Stent</brief_title>
	<detailed_description>Recent autopsy study show important histological morphometric predictor stent thrombosis endothelial coverage ratio uncover total strut drug elute stent ( DES ) implantation . Although controversy , incomplete stent apposition might possible cause late stent thrombosis DES implantation . Therefore , theoretically dual antiplatelet therapy continue prevent stent thrombosis complete reendothelialization . But , detection endothelial coverage stent possible available intravascular device clinical practice . Among currently available intravascular device , intravascular optical coherence tomography ( OCT ) could give clear identification thin layer NIH malapposition high-resolution ( 10 -20 μm ) compare intravascular ultrasound ( 100-150 μm ) . Previous OCT study show significant different pattern neointimal coverage bare metal stent ( BMS ) DES . In experience , also differences neointimal coverage among DESs , especially zotarolimus elute stent ( ZES ) . ZES know associate significantly neointimal coverage SES 8 month intravascular ultrasound ( IVUS ) . This finding might relate strut thickness drug elution property . In data , neointima cover 99.7 % stent strut ZES , 93.2 % sirolimus elute stent ( SES ) 9 month follow OCT . This difference distinct patient acute myocardial infarction ( 99.3 % ZES vs.79.9 % SES ) . Both everolimus eluting stent ( EES ) recently introduce ZES resolute also available near future Korea . Previous phosphorylcholine polymer replace new , proprietary polymer provide extend elution kinetics ZES resolute . Therefore , efficacy suppress neointimal growth might improve , safety neointimal coverage need evaluate human coronary artery . Both new DESs cobalt chromium stent thin stent strut report similar efficacy suppress neointima growth . Also , endothelial coverage stent strut occur early compare previous DESs ( SES PES ) animal experiment . But , data neointimal coverage malapposition ZES resolute EES use OCT human coronary artery . Recent paper accord Kubo et al report serial OCT examination demonstrate markedly different vascular response 9 month SES implantation unstable angina stable angina patient . These finding imply initial native vessel status , cover stent , might important relate neointimal coverage malapposition . But , little data evaluate relationship initial lesion status neointimal coverage late malapposition OCT . Therefore , study investigates : 1 ) relationship initial lesion neointimal coverage late malapposition 2 ) neointimal coverage malapposition 9 month ZES resolute EES implantation 3 ) compare ZES resolute EES 9 month stent implantation . Study Objectives : This study prospective open label randomize study compare neointimal coverage ZES resolute ( Endeavor® resolute ) EES ( Xience® ) 9 month stent implantation OCT. 1 . Primary end point : - The primary endpoint compare neointimal coverage ZES resolute ( Endeavor® resolute ) EES ( Xience® ) 9 month stent implantation OCT. 2 . Secondary end point : - To investigate relationship initial lesion neointimal coverage malapposition 9 month , - To compare neointimal growth ZES resolute EES 9 month compare difference early late malapposition ZES resolute EES 9 month .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Significant coronary de novo lesion ( &gt; 70 % quantitative angiographic analysis ) Patients stable acute coronary syndrome consider coronary revascularization Reference vessel diameter 2.5 3.5 mm operator assessment The criterion exclusion contraindication antiplatelet agent Proximal lesion within 15 mm ostium Different DES vessel simultaneously Creatinine level 2.0 mg/dL ESRD Severe hepatic dysfunction ( 3 time normal reference value ) Pregnant woman woman potential childbearing Life expectancy 1 year Complex lesion morphology ( aortoostial , bifurcation &gt; 2.0 mm side branch , unprotected leave main , thrombus , severe calcification , chronic total occlusion ) Target lesion vein graft lesion Reference vessel &lt; 2.5 mm &gt; 4.0 mm diameter visual Long lesion require two stent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>